IMMUCELL CORP
ICCCNASDAQTrading Snapshot
- Day Range
- $9.83 – $10.12
- 52-Week Range
- $4.52 – $12.10
- Volume
- $3.62B
- Avg Volume
- $3.66B
- Shares Outstanding
- 9.0M
- Next Earnings
- Nov 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $28M
- Last Q Revenue
- $7M
- P/E Ratio
- 116.8
- P/S Ratio
- 2.9x
- EPS (TTM)
- $0.09
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.2%
Why Investors Own ICCC
- ✓High-growth profile — revenue up -9.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IMMUCELL CORP
ICCC
StockOtter · stockotter.spaceAbout IMMUCELL CORP
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
ICCC's Q2 sales rise 11.5% y/y, but margins contract. A $2-million legal settlement boosts profit as the company plans a capacity expansion.
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
ImmuCell Corporation (NASDAQ: ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $8.64 and traded as high as $10.49. ImmuCel
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell Corporation (ICCC) Q2 2026 Earnings Call Transcript
ImmuCell Q2 Earnings Call Highlights
ImmuCell NASDAQ: ICCC reported higher second-quarter sales and earnings as domestic demand for its calf scours prevention products increased, while the company outlined plans to invest about $8 million to more than tripl
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf he
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf he